The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the Phase II EMN19 trial (NCT04166565), which is assessing the treatment of extramedullary disease (EMD) in multiple myeloma (MM) with daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd). Dr Beksac highlights the impact of combining complete metabolic response (CMR) with marrow measurable residual disease (MRD) to analyze patient outcome. Patients who achieved both demonstrated an improvement in progression-free survival (PFS) over those who only achieved one or none of these. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: BMS, Takeda, Amgen; Advisory Board: Pfizer, Menarini, Janssen; Speakers Bureau: Janssen.
